Immunophenotyping in acute myeloblastic leukemia: Review; [Akut miyeloblastik lösemide i̇mmünofenotipik deǧerlendirme]

Simple item page
dc.contributor.authorGülen H.
dc.date.accessioned2024-07-22T08:20:39Z
dc.date.available2024-07-22T08:20:39Z
dc.date.issued2010
dc.description.abstractAcute myeloid leukemia is a heterogeneous disease, presenting with a high diversity of phenotypes. Immunophenotyping is essential for diagnosis and definition of particular myeloid leukemia subtypes such as M0, M7 and M3 variants which cannot be defined by cytomorphology or cytochemistry alone. M0 blasts show minimally antigenic differentiation and also morphologically resemble to FAB L1/L2 blasts of lymphoblastic leukemia. Additionally, it can express TdT and lymphoid associated antigens such as CD2, CD4, CD7, CD10, CD19 and can be diagnosed falsely as myeloid antigen positive lymphoblastic leukemia. cyCD3, CD5 and cyCD79a antigens are the best markers in differantation of M0 and lymphoblastic leukemia. HLA-DR and CD34 are the best markers in differantation of M3 and other subtypes of myeloid leukemia. In this sense, CD14 is also a valuable marker, because it is not reported in any case of promyelocytic leukemia. M7 subtypes of myeloid leukemia can not be diagnosed by routine cytochemical dyes unless immunophenotyping. The establishing of CD41 (gpIIb) and/or CD61( gpIIIa)positivity and myeloperoxidase negativity on blasts by immunophenotyping can confirm megakaryoblastic leukemia diagnosis. Recently, immunophenotyping of blast cells by flow cytometry plays an increasing role in diagnosis and following of minimal residual disease. The antigens assosciated with poor prognosis in myeloid leukemia are CD7, CD56 and CD34. A phenotype of CD117+CD34+CD15+ is expressed in many myeloid leukemia subgroups and is used in following of minimally residual disease during remission. In conclusion, CD13, CD33, HLA-DR, CD34, CD117, CD11, CD14, CD15, CD41, CD61, MPO, CD65, cyCD3, CD7, cyCD79a, and CD19 markers should be studied in all cases of myeloid leukemia at presentation. Copyright © 2010 by Türkiye Klinikleri.
dc.identifier.issn13000381
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/18267
dc.language.isoTurkish
dc.subjectCD19 antigen
dc.subjectCD2 antigen
dc.subjectCD34 antigen
dc.subjectCD4 antigen
dc.subjectCD61 antigen
dc.subjectCD7 antigen
dc.subjectcommon acute lymphoblastic leukemia antigen
dc.subjectfibrinogen receptor
dc.subjectHLA DR antigen
dc.subjectacute megakaryocytic leukemia
dc.subjectacute myeloblastic leukemia
dc.subjectcytochemistry
dc.subjecthuman
dc.subjectimmunophenotyping
dc.subjectmyeloid leukemia
dc.subjectphenotype
dc.subjectreview
dc.titleImmunophenotyping in acute myeloblastic leukemia: Review; [Akut miyeloblastik lösemide i̇mmünofenotipik deǧerlendirme]
dc.typeReview

Files

Collections

Scopus Koleksiyonu